• 1
    Sibbald B, Rink E. Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history. Thorax 1991;46:895901.
  • 2
    Dahl R. Rhinitis and Asthma. In: editors.MygindN, NaclerioR Allergic and non-allergic rhinitis. Copenhagen : Munksgaard. 1993;1848.
  • 3
    Settipane GA. Nasal manifestations of systemic disease. In: SettipaneGA, editor. Rhinitis. Providence , RI : OceanSide Publications, 1991;197207.
  • 4
    Naclerio R. Solomon W. Rhinitis and inhalant allergens. JAMA 1997;227:18428.
  • 5
    Naclerio RM. Pathophysiology of perennial allergic rhinitis. Allergy 1997;52 Suppl 36:713.
  • 6
    Rowe-Jones JM. The link between the nose and lung, perennial rhinitis and asthma - is it the same disease Allergy 1997;52 Suppl 36:208.
  • 7
    International Rhinitis Management Working Group. Treatment of allergie rhinitis. Allergy 1994;49 Suppl 19:1923.
  • 8
    van Cauwenberge P, Wang D. Antihistamines and nasal blockage. Allergy 1997;52 Suppl 40:358.
  • 9
    Specior SL. Allergic and nonallergie rhinitis: update on pathophysiology and clinical management. Am J Ther 1995;2:2905.
  • 10
    Baraniuk JN, Meltzer EO, Spector SL. Putting together an effective plan for managing allergic rhinitis. J Respir Dis 1996;17 Suppl 8:S3444.
  • 11
    Rosenzweig P, Thébault JJ, Caplain H. et al. Pharmacodynamics and pharmaeokinetics of mizolastine (SL.85.0324), a new nonsedative H1 antihistamine. Ann Allergy 1992;69:1359.
  • 12
    Mesnil F, Dubruc C, Mentre F, Huet S, Mallet A, Thénot JP. Pharmacokinetic analysis of mizolastine in healthy young volunteers after single oral and intravenous doses: noncompartmental approach and compartmental modeling. Pharmaeokin Biopharm 1997;25:12547.
  • 13
    Rosensweig P, Guillaume M, Brohier S, Ulliac N, Cabanis MJ, Thébault JJ. Comparative whcal and flare study of mizolastine versus terfenadine, cetirizine, loratadine and placebo in healthy volunteers. Br J Clin Pharmacol 1995;40:45965.
  • 14
    Bousquet J, Chanal I, Murrieta M, Stalla-Bourdillon A. Lack of subsensitivity to mizolastine over 8-week treatment. Allergy 1995;51:2516.
  • 15
    Patat A, Gram LF, Dubruc C, Brohier S, Cabanis MJ, Rosenzweig P. Effect of mizolastine, a new antihistamine, on psychomotor performance and memory in elderly subjects. Int Clin Psychopharmacol 1994;9:1018.
  • 16
    Schaffler K, Wausehkuhn CH, Zander KJ, et al. CNS-pharmacodynamics and pharmaeokinetics of the new nonsedative H1-antagonist SL.85.0324 vs placebo and dimetinden in volunteers. Eur J Pharmacol 1990;183:5934.
  • 17
    Vuurman P, Rosenzweig P, O'Hanlon JF Mizolastine's effects on psychomotor and actual driving performance in healthy volunteers after single 5, 10, 20 and 40 mg doses vs clemastine 2 mg and placebo. Eur J Clin Immunol 1993;48:30.
  • 18
    Kerr JS, Dunmore C, Hindmarch I. The psychomotor and cognitive effects of a new antihistamine, mizolastine, compared to terfenadine, triprolidine and placebo in healthy volunteers. Eur J Clin Pharmaeol 1994;47:3315.
  • 19
    Stern MA. Darnell R, Tudor D. Can an antihistamine delay appearance of hay fever symptoms when given prior to pollen season Allergy 1997;52:4404.
  • 20
    Leynadier F, Bousquet J, Murrieta M, Attali P, RHINASE study group. Efficacy and safety of mizolatine in seasonal allergic rhinitis. Ann Allergy 1996;76:1638.
  • 21
    Bellioni P. Catalano B, Cervellera G, Filiaci F, Mira E, Carraro A. Comparison of mizolastine with loratadine in the treatment of perennial allergic rhinitis. Rhinology 1996;34:1014.
  • 22
    Brostoff J, Fitzharris P Dunmore C, Théron M, Blondin P. Efficacy of mizolastine. a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria. Allergy 1996;51:3205.
  • 23
    Vargaftig BB. Mechanisms of experimental bronchopulmonary hyperresponsiveness as related to eosinophils. In: LangerSZ, ChurchMK, VargaftigBB, NicosiaS, editors. New developments in the therapy of allergic disorders and asthma. Int Acad Biomed Drug Res 1993;6:2732.
  • 24
    Pichat P, Angel I, Arbilla S. Antiinflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat. Arzn Forsch Drug Res 1998;48:1738.
  • 25
    Goldhill J, Pichat P, Roome N, Angel I, Arbilla S. Effect of mizolastine on visceral sensory afferent sensitivity and inflammation during experimental colitis. Arzn Forsch Drug Res 1998;48:17984.
  • 26
    Michel L, Murrieta-Aguttes M, Jean-Louis F, Dubertret L, Verrechia M. Inhibitory effect of oral mizolastine (M) on in vivo antigen-induced soluble ICAM-1 release in human skin (skin chamber technique) [Abstract]. Allergy 1996;51 Suppl 31:373.
  • 27
    Costa JJ, Weller PF, Galli SJ. The cells of the allergic response. JAMA 1997;227:181521.
  • 28
    Juniper EF. Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol 1997;99:S7429.